ClinicalTrials.gg
CompletedNCT05444049ARISEUpdated Oct 9, 2025

NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)

An interventional study of NEURESCUE device in Cardiac Arrest, Cardiopulmonary Arrest and Cardiovascular Diseases, sponsored by neurescue. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by neurescue · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.

Enrollment
107th of 117
6 · median 72
Started
2022
with 4 others
No phase
67 of 171
15 open now
Registered
125th of 171
by date

Among the 171 studies in Heart Arrest with a site in United States, this one is the 107th largest by enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2022, is one of 67 with no phase, and was the 125th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Heart Arrest with a site in United States, or all of them as a file.
02

Study summary

The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.

The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.

The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.

03

Conditions studied

  • Cardiac Arrest
  • Cardiopulmonary Arrest
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤80 years
  2. CPR initiated within 7 min of presumed arrest
  3. 8 min of continuous ACLS without ROSC

Exclusion criteria

Exclusion Criteria:

  1. Traumatic cardiac arrest
  2. Intraoperative cardiac arrest
  3. Known pregnancy
  4. Known terminal disease
  5. Known do-not-attempt-CPR order
  6. Subjects whose femoral arterial access site cannot accommodate an 8 Fr introducer sheath
  7. Subjects currently on mechanical circulatory support
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Treatment

    The NEURESCUE device will be used as an adjunct to ACLS.

    Device: NEURESCUE device

Interventions

  • DeviceNEURESCUE device

    The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.

06

What researchers measure

Primary outcomes

  1. Successful balloon inflation within 10 minutes from first vessel puncture

    Time frame: Assessed up to 10 min

Secondary outcomes

  1. Change in central blood pressure

    Time frame: Assessed up to 1 hour

  2. Total ACLS time at initiation of the investigational procedure

    Time frame: Assessed up to 1 hour

  3. Time from first vessel puncture to successful sheath insertion

    Time frame: Assessed up to 1 hour

  4. Rate of occlusion success

    Time frame: Assessed up to 1 hour

  5. Return of spontaneous circulation (ROSC)

    The endpoint is dichotomous (yes/no) for each subject

    Time frame: Assessed up to 1 hour

07

Study locations

1 site
  • Long Beach Medical Center
    Long Beach, California 90806, United States
08

References and documents

Publications

  • Rusnak J, Thevathasan T, Skurk C, Zelniker TA, Frost H, Eden M, Speer C, Frey N, Preusch MR. Feasibility of computer-aided aortic occlusion catheter in non-traumatic cardiac arrest. Resuscitation. 2025 Dec;217:110879. doi: 10.1016/j.resuscitation.2025.110879. Epub 2025 Nov 12. PubMed 41237845 ↗

Individual participant data

Plan to share: No — Individual request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2024, 21 months.

Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 5, 2022
StartActual
Dec 8, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444049
Lead sponsor
neurescue
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Dec 8, 2022
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Oct 9, 2025

Study contacts

David Shavelle, M.D.
principal investigator · Long Beach Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion